|
|
||||||||
From the Departments of Clinical Neurosciences (Drs. Biary, Bahou, Sofi, and Al Deeb) and Pharmacy (Dr. Thomas), Armed Forces Hospital, Riyadh, Kingdom of Saudi Arabia.
Presented in part at the 46th annual meeting of the American Academy of Neurology, Washington, DC, May 1994.
Received July 26, 1994. Accepted in final form January 16, 1995.
Address correspondence and reprint requests to Dr. Nabil Biary, Consultant Neurologist, Department of Clinical Neurosciences, Armed Forces Hospital, PO Box 7897, Riyadh 11159, Kingdom of Saudi Arabia.
We investigated the effect of nimodipine (30 mg qid) in 16 de novo patients with essential tremor in a double-blind placebo-controlled study in which we assessed tremor by clinical scorings, tremorgraphic recordings, and patient self-evaluation. Of the 15 patients who completed the study, eight improved. We conclude that nimodipine is effective in some patients with essential tremor.
NEUROLOGY 1995;45: 1523-1525
This article has been cited by other articles:
![]() |
A. Gironell and J. Kulisevsky Review: Diagnosis and management of essential tremor and dystonic tremor Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 215 - 222. [Abstract] [PDF] |
||||
![]() |
A. Shatunov, N. Sambuughin, J. Jankovic, R. Elble, H. S. Lee, A. B. Singleton, A. Dagvadorj, J. Ji, Y. Zhang, V. E. Kimonis, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23 Brain, September 1, 2006; 129(9): 2318 - 2331. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Louis Essential Tremor N. Engl. J. Med., September 20, 2001; 345(12): 887 - 891. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |